CMAJ • October 26, 2004; 171 (9). doi:10.1503/cmaj.1040563.
© 2004 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh, S. M.
Right arrow Articles by Harris, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, S. M.
Right arrow Articles by Harris, H.
Related Collections
Right arrow Inflammatory bowel disease
Right arrow Adverse drug reactions
Right arrowRelated Article

Research
Recherche

Case report

Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone

Sheldon M. Singh, Neil V. Rau, Lawrence B. Cohen and Howard Harris

From the Department of Medicine, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ont. (Singh, Cohen), the Halton Healthcare Services, Oakville, Ont., and the Credit Valley Hospital, Mississauga, Ont. (Rau, Harris)

INFLIXIMAB IS A CHIMERIC ANTI-TUMOUR NECROSIS FACTOR-{alpha} antibody that is efficacious in treating Crohn's disease. However, its immunomodulatory properties increase susceptibility to opportunistic infections. We present a case of cutaneous Nocardia infection in a patient who was taking infliximab for Crohn's disease. The case illustrates the challenges in the diagnosis and management of this disease and serves as a reminder of the complications associated with the use of immunomodulatory agents.


Related Article

Infliximab and serious hematologic events
Cynthia Phelan and Eric Wooltorton
Can. Med. Assoc. J. 2004 171: 1045. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 QJMHome page
I. Marie, L. Lahaxe, H. Levesque, and P. Heliot
Pulmonary actinomycosis in a patient with diffuse systemic sclerosis treated with infliximab
QJM, May 1, 2008; 101(5): 419 - 421.
[Full Text] [PDF]